文献速递腹部MR

钆塞酸增强肝脏MRI与扩散加权成像上化疗后消失或残留微小(≤5 mm)结直肠癌肝转移灶:是否需要局部治疗?

Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?
PubMed 文献 · Eur Radiol · 2016-11-04

研究纳入137例化疗后行钆塞酸增强MRI及DWI的结直肠癌肝转移患者,其中43例共168个消失病灶和48个残留微小病灶。未追加治疗随访显示,消失病灶1年及2年原位复发率分别为10.9%和15.7%,残留微小病灶2年进展率为33.2%;无化疗所致肝窦阻塞综合征者消失病灶2年原位复发率为4.9%。

要点

  • 钆塞酸增强MRI及DWI上消失的结直肠癌肝转移灶2年原位复发率仅15.7%,提示临床完全缓解可能性高。
  • 残留微小(≤5 mm)病灶2年进展率达33.2%,与消失病灶的临床过程不同。
  • 无肝窦阻塞综合征者消失病灶2年原位复发率为4.9%,合并肝窦阻塞综合征时需特别关注。

核心结论

  • 钆塞酸增强肝脏MRI及DWI上消失的结直肠癌肝转移灶提示临床完全缓解可能性高,尤其无化疗所致肝窦阻塞综合征者;残留微小病灶2年进展率为33.2%。

研究设计与样本

  • 研究纳入2010至2012年间因结直肠癌肝转移接受化疗并完成钆塞酸增强MRI及DWI的137例患者中的43例,共168个消失病灶和48个残留微小病灶,评估累积原位复发率、进展率及预测因素。

关键影像表现/征象

  • 消失病灶在肝胆期可表现为肝实质网状低信号,该征象与化疗所致肝窦阻塞综合征相关。
  • 共150个消失病灶和26个残留微小病灶未追加治疗而进入随访。

诊断标准与关键数值

  • 消失病灶1年及2年累积原位复发率分别为10.9%和15.7%。
  • 残留微小病灶1年及2年累积进展率分别为27.2%和33.2%。
  • 无肝胆期肝实质网状低信号的消失病灶组2年原位复发率为4.9%。

临床应用与阅片要点

  • 阅片时需区分钆塞酸增强MRI及DWI上消失的病灶与残留微小(≤5 mm)病灶,二者临床过程不同。
  • 肝胆期出现肝实质网状低信号(提示肝窦阻塞综合征)时,对消失病灶的评估需特别谨慎。
  • 残留微小病灶2年进展率约三分之一,随访中需关注其变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the clinical course of disappearing colorectal liver metastases (DLM) or residual tiny (≤5 mm) colorectal liver metastases (RTCLM) on gadoxetic acid-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in patients who had colorectal liver metastases (CLM) and received chemotherapy.

METHODS: Among 137 patients who received chemotherapy for CLM and underwent gadoxetic acid-enhanced MRI and DWI between 2010 and 2012, 43 patients with 168 DLMs and 48 RTCLMs were included. The cumulative in situ recurrence rate of DLM and progression rate of RTCLM and their predictive factors were evaluated.

RESULTS: A total of 150 DLMs and 26 RTCLMs were followed up without additional treatment. At 1 and 2 years, respectively, the cumulative in situ recurrence rates for DLM were 10.9 % and 15.7 % and the cumulative progression rates for RTCLM were 27.2 % and 33.2 %. The in situ recurrence rate at 2 years was 4.9 % for the DLM group that did not show reticular hypointensity of liver parenchyma on hepatobiliary phase.

CONCLUSIONS: DLM on gadoxetic acid-enhanced liver MRI and DWI indicates a high possibility of clinical complete response, especially in patients without chemotherapy-induced sinusoidal obstruction syndrome. Thirty-three percent of RTCLMs showed progression at 2 years.

KEY POINTS: • DLMs on gadoxetic acid-enhanced MRI and DWI showed low recurrence rates. • If there is sinusoidal obstruction syndrome, evaluation of DLM needs special care. • The progression rate for residual tiny CLMs was 33.2 % at 2 years.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim SS, Song KD, Kim YK, et al. Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required? Eur Radiol. 2016. PMID: 27815722. doi:10.1007/s00330-016-4644-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。